ArticlePediatric rheumatology online journal2026
Anti-adalimumab antibodies are associated with loss of response in juvenile idiopathic arthritis.
Article in Pediatric rheumatology online journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSecondary drug failure to adalimumab remains a significant challenge in managing Juvenile Idiopatihc Arthritis (JIA), with anti-adalimumab antibodies (ADA_ab) implicated as a potential mechanism. This study examines the relationship between ADA_ab formation and loss of response (LOR).
findingsIn this retrospective, longitudinal study, a combination of conventional statistical methods and machine-learning algorithms were employed to investigate the association of adalimumab drug levels (ADA_drug) and ADA_ab, alongside clinical variables, on LOR among JIA patients treated between December 2016 and May 2024. LOR was defined as active disease. Among 184 patients, ADA_ab and ADA_drug emerged as the strongest predictors of LOR in random-forest analysis. In multiple logistic regression, higher ADA_ab levels were independently associated with increased risk of LOR (OR 1.18, 95% CI 1.08–1.29, p = 0.0003), while higher ADA_drug levels were associated with reduced risk (OR 0.81, 95% CI 0.68–0.95, p = 0.0103). An ADA_ab threshold of 69 AU/mL was associated with an eightfold increase in LOR (OR 8.04, 95% CI 2.8–26.1, p = 0.0002). Patients with high ADA_ab and undetectable ADA_drug had the highest risk of LOR (OR 28.24, 95% CI 7.11–111.63, p = 0.0001). Kaplan–Meier analysis demonstrated that 71% of patients with elevated ADA_ab experienced LOR within 12 months
conclusionHigh ADA_ab levels are a significant predictor of LOR in JIA patients treated with adalimumab, particularly when coupled with low drug levels. We also report clinically meaningful one-year LOR rates. These findings support the use of therapeutic drug monitoring, which may help optimise treatment and improve long-term disease control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.